Challenges and new discoveries in the treatment of leishmaniasis

Journal of Infection and Chemotherapy

Volumn 10, Issue 6, 2004, Pages 307-315

  Singh, Sarman ^a   Sivakumar, Ramu ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Amphotericin B; Edelfosine; HIV; Kala Azar; Miltefosine; Sodium antimony gluconate

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; ANTIMONY GLUCONATE; ANTINEOPLASTIC AGENT; CLOTRIMAZOLE; DEOXYCHOLIC ACID; IMIDAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; METRONIDAZOLE; MICONAZOLE; MILTEFOSINE; OCTADECYLPHOSPHOCHOLINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PHOSPHORYLCHOLINE; RECOMBINANT GAMMA INTERFERON; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; UREA STIBAMINE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BONE PAIN; BURNING SENSATION; CARDIOTOXICITY; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFUSION; COST BENEFIT ANALYSIS; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOCRINE DISEASE; FLAGELLATE; GASTROINTESTINAL SYMPTOM; HEART ARREST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INDIA; INFECTION; INJECTION SITE REACTION; LEISHMANIA; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIASIS; LIVER TOXICITY; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; PAIN; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHLEBOTOMUS; PREGNANCY; PREVALENCE; PRURITUS; PSYCHODIDAE; REVIEW; SIDE EFFECT; SKIN LEISHMANIASIS; TACHYCARDIA; TASTE DISORDER; VESTIBULOCOCHLEAR NERVE DISEASE; VISCERAL LEISHMANIASIS; VOMITING;

EID: 12444261681     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0348-9     Document Type: Review

References (64)

1. Geographical distribution of leishmaniasis. Geneva: WHO. Available at: http://www.who.int/emc/diseases/leish/leisgeo.html.
2. Herwaldt BL. Leishmaniasis. Lancet. 1999;354(9185):1191-9.
3. World Health Organization. Control of the leishmaniasis. Expert committee. WHO Tech Rep Series 1990;793:27.
4. Peter W. The treatment of kala-azar: new approach to an old problem. Ind J Med Res. 1981;73(suppl):1-18.
5. Sanyal RK. Leishmaniasis in the Indian subcontinent. In: Chang KP, Bray RS, editors. Leishmaniasis. Amsterdam: Elsevier; 1985. p. 443-67.
6. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984;78:391-8.
7. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995;34:85-91.
8. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. J Postgrad Med 2003;49:39-49.
9. Singh S, Chaudhary VP, Wali JP. Transfusion-transmitted Kala-azar in India. Transfusion 1996;36:848-9.
10. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg 1991;45:435-41.
11. Thakur CP. Drug resistance in kala-azar: an overviews. In: Gupta S, Sood OP, editors. Proceedings of round table conference series. No. 5. New Delhi: Ranbaxy Science Foundation: 1999. p. 27-33.
12. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296-306.
13. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
14. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:83-90.
15. Brummitt CF, Porter JA, Herwaldt BL. Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Clin Infect Dis 1996;22:878-9.
16. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:167-70.
17. Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991;39:314-6.
18. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994;50:107-11.
19. Sundar S. Treatment of visceral leishmaniasis. Med Microbiol Immunol (Berl) 2001;190:89-92.
20. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992;340 (8830):1256-7.
21. Thakur CP, Sinha GP, Sharma V, Pandey AK, Sinha PK, Barat D. Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life. Indian J Pediatr 1993;60:29-36.
22. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994;344(8937):1599-600.
23. Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 1994;19:560.
24. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21:188-93.
25. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
26. Sundar S, Agrawal G, Sinha PR, Horwith GS, Murray HW. Short course low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133-7.
27. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84:221-5.
28. Scott JA, Davidson RN, Moody AH, Grant HR, Felmingham D, Scott GM, et al. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg 1992;86:617-9.
29. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barrai A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990;322(1): 16-21.
30. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis 1995;172(6):1627-9.
31. Singh S, Kumar J, Singh R. Dwivedi SN. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable antileishmanial drugs: a community-based study. Int J Infect Dis 2000;4:203-8.
32. Mishra M, Thakur BD, Choudhary M. Metronidazole and Indian kala-azar: results of a clinical trial. Br Med J (Clin Res Ed) 1985;291:1611.
33. Thakur CP, Sinha PK. Inefficacy of ethambutol, ethambutol plus isoniazid, INH plus rifampicin, co-trimoxazole and metronidazole in the treatment of kala-azar. Am J Trop Med Hyg 1989;92:383-5.
34. Jha TK. Evaluation of Allopurinol in treatment of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:204-7.
35. Weinrauch L, Livishin R, El-On J. Ketoconazole in cutaneous leishmaniasis. Br J Dermatol 1987;117:666-7.
36. Akuffo H, Dietz M, Teklemariam S, Tadesse T, Amare G, Berhan TY. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1990;84:532-4.
37. Wali JP, Aggarwal P, Gupta U, Saluja S, Singh S. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. J Infect Dis 1992;166:215-6.
38. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet 1996;348(9027): 614.
39. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65:685-9.
40. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related compounds against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6.
41. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyl-phospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996;38:1041-7.
42. Singh S. Alkylphosphocholine in visceral leishmaniasis: in-vitro and in-vivo study. J Parasit Dis 1996;20:185-8.
43. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341(24):1795-800.
44. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347(22):1739-46.
45. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002;8:319-42.
46. Rosenthal E, Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003;49:61-8.
47. Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D, et al. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998;42:654-8.
48. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003;22:380-7.
49. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986;87(2):284-8.
50. Faris RM, Jarallah JS, Khoja TA, al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993;32:610-2.
51. Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman JD. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. Am J Trop Med Hyg 1991;45:92-7.
52. Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 1995;20:47-51.
53. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-6.
54. Bryceson AD, Murphy A, Moody AH. Treatment of "Old World" cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994;88(2):226-8.
55. Bryceson A. Current issues in the treatment of visceral leishmaniasis. Med Microbiol Immunol 2001;190:81-4.
56. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001;65:466-70.
57. Pal C, Raha M, Basu A, Roy KC, Gupta A, Ghosh M, et al. Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters. Antimicrob Agents Chemother 2002;46:259-61.
58. Becker I, Volkow P, Velasco-Castrejon O, Salaiza-Suazo N, Berzunza-Cruz M, Dominguez JS, et al. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitol Res 1999;85:165-70.
59. Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001;49:609-13.
60. Singh S. Mucosal Leishmaniasis in an Indian AIDS patient. Lancet Infect DIS 2004;4(11):660-1.
61. Russo R, Nigro L, Panarello G, Montineri A. Clinical survey of leishmania/HIV co-infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasitol 2003;97(suppl 1):149-55.
62. del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al. French Hospital Database on HIV Clinical Epidemiologic Group. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002;186(9):1366-70.
63. Tortajada C. Perez-Cuevas B, Moreno A, Martinez E, Mallolas J, Garcia F, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:364-6.
64. Das A, Mandal C, Dasgupta A, Sengupta T, Majumder HK. An insight into the active site of a type I DNA topoisomerase from the kinetoplastid protozoan Leishmania donovani. Nucleic Acids Res 2002;30(3):794-802.